Versigent (NYSE:VGNT – Get Free Report) shares were up 10.2% on Wednesday . The stock traded as high as $49.92 and last traded at $49.7680. Approximately 2,825,330 shares traded hands during mid-day trading, an increase of 7% from the average daily volume of 2,647,249 shares. The stock had previously closed at $45.16.
Analysts Set New Price Targets
Several equities research analysts have weighed in on VGNT shares. BNP Paribas Exane started coverage on shares of Versigent in a report on Tuesday, April 28th. They issued an “outperform” rating and a $41.00 target price on the stock. TD Cowen increased their target price on shares of Versigent from $47.00 to $49.00 and gave the stock a “buy” rating in a report on Wednesday, May 6th. UBS Group increased their target price on shares of Versigent from $49.00 to $58.00 and gave the stock a “buy” rating in a report on Friday. Evercore reiterated an “outperform” rating and issued a $60.00 target price on shares of Versigent in a report on Monday, May 18th. Finally, Zacks Research upgraded shares of Versigent to a “hold” rating in a report on Thursday, April 16th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, Versigent presently has an average rating of “Moderate Buy” and an average price target of $46.67.
View Our Latest Stock Analysis on Versigent
Versigent Stock Performance
Versigent (NYSE:VGNT – Get Free Report) last issued its quarterly earnings data on Tuesday, May 5th. The company reported $999.00 EPS for the quarter.
Featured Articles
- Five stocks we like better than Versigent
- AI Server Earnings: Wall Street Sees One Clear Standout
- Navitas: NVIDIA’s AI Power Broker?
- A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below
- NVIDIA’s New Power Play: Why Fluence Is Surging
Receive News & Ratings for Versigent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versigent and related companies with MarketBeat.com's FREE daily email newsletter.
